Navigation Links
Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

SAN DIEGO, July 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009 at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:          Jack Lief
                       President and Chief Executive Officer

                       Cindy McGee
                       Senior Communications Associate

                       Arena Pharmaceuticals, Inc.
                       858.453.7200, ext. 1479

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
2. AHIMA Enters Multinational Arena to Support HIM Worldwide Advancement
3. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Arena Pharmaceuticals Announces Public Offering of Common Stock
5. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
6. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
7. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
8. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
9. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
10. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: ... enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting through ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant ... , The order will be from the China Disabled Persons’ Federation, a central ... an effective solution for children and adults suffering from severe and profound hearing ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... and Brooke Bennett are collaborating with brands across various categories through traditional and ... figures make up an elite group of Gold Medal Moms who can connect ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Dale Jones as a 2015-2016 inductee into its ... for leadership in education. NAPW is the nation’s leading networking organization exclusively for ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015  Today, AmerisourceBergen, a global ... a first-of-its-kind population health management program focused on ... to be built into existing employer benefit packages, ... for their care and explains how to avoid ... to help patients understand their treatment options and ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
(Date:12/1/2015)... WASHINGTON and TELTOW, Germany ... SensoMotoric Instruments (SMI) , a leading global manufacturer of ... RightEye LLC has included SMI remote eye trackers ... that help healthcare providers assess concussions, eye sight, and ... SMI RED -oem technology is part of SMI,s mass-market-ready ...
Breaking Medicine Technology: